Genmab A/S Announces Data From Its Phase 3 LiGeR-HN1 Study Of Petosemtamab Demonstrates 50% Death Risk Reduction For Treatment Of Head And Neck Squamous Cell Carcinoma

Loading news article.

Genmab A/S Announces Data From Its Phase 3 LiGeR-HN1 Study Of Petosemtamab Demonstrates 50% Death Risk Reduction For Treatment Of Head And Neck Squamous Cell Carcinoma | WAPE

Genmab A/S Announces Data From Its Phase 3 LiGeR-HN1 Study Of Petosemtamab Demonstrates 50% Death Risk Reduction For Treatment Of Head And Neck Squamous Cell Carcinoma

Article summary

Related companies

Comments —